

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Confirmation No. 6787

Takanori TABUCHI et al.

Attorney Docket No. 2005 0058A

Serial No. 10/522,798

Group Art Unit 1642

Filed February 28, 2005

Examiner Not Yet Assigned

NOVEL PROCESS FOR PRODUCING

Mail Stop: Amendment

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

[]	each U.S. Patent and U.S. Patent application publication;
[]	each reference previously cited in the international application PCT/; and/or
[]	each reference previously cited in prior parent application Serial No.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
  - a. [] that each item of information contained in this Information Disclosure

    Statement was first cited in any communication from a foreign patent office in a
    counterpart foreign application not more than three months prior to the filing of
    the Statement, or
  - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4.		For each non-English language reference listed on the attached form PTO-1449, reference is made to:								
	a.		a full or partial English language translation submitted herewith,							
	b.	[]	a foreign patent office search report (in the English language) submitted herewith,							
	c.	[]	the concise explanation contained in the specification of the present application at page,							
	d.		the concise explanation set forth in the attached English language abstract,							
	e.		the concise explanation set forth below or on a separate sheet attached to the reference:							

- 5. [X] A foreign patent office search report citing one or more of the references is enclosed along with the English translation of the International Preliminary Examination Report.
- Statement Under 37 CFR 1.704(d) 6.

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Takanori TABUCHI et al.

By Warren M. Cheek, Jr. Registration No. 33,367 Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 February 21, 2007

Sheet 1 of 1			INFORMA	TION DISCLOSURE	STATEMENT			O 15K		
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET N 2005_0058A	SERIAL 1 10/522,	NO. 798	FEB 2 1 2007	NP 99		
PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Takanori TABUCHI et al.					3/	
(Use several sheets if necessary)  Date Submitted to PTO: February 21, 2007				FILING DATE February 28, 2	GROUP					
			U.	S. PATENT DOCUM			I			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME					FILING DATE IF APPROPRIATE	
	AA									
	АВ									
	AC									
	AD									
	AE									
	AF	_								
	AG									
	АН									
	Al									
			FORE	EIGN PATENT DOC	JMENTS			Ī		
								TRANSLA YES	RANSLATION YES NO	
	AJ									
	AK									
	AL									
	АМ					_				
	AN									
		OTHER	DOCUMENT(S) (I	Including Author, Title	e, Date, Pertinent Pag	es, Etc.)	· ·			
	AO	K. Tamao et al., "Nickel-Phosphine Complex-Catalyzed Grignard Coupling. I. Cross-Coupling of Alkyl, Aryl, and Alkenyl Grignard Reagents with Aryl and Alkenyl Halides: General Scope and Limitations", Vol. 49, No. 7, pp. 1958-1969, July 1979.								
	AP									
	AQ									
EXAMINER				DATE CONSIDERED						